Loading data
NERVNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development expense | 5.76 m USD | 11.9 m USD | 12.71 m USD | 14.65 m USD | 32.04 m USD |
| Operating profit | -15.1 m USD | -21.85 m USD | -23.12 m USD | -25.23 m USD | -45.37 m USD |
| Profit before tax | — | — | — | -32.11 m USD | -51.71 m USD |
| Income tax expense | — | — | — | — | -1.8 m USD |
| Net income (reported basis) | -293.42 m USD | 1.44 m USD | -30.01 m USD | -32.11 m USD | -49.91 m USD |
| Basic earnings per share | -34.67 USD/share | 0.19 USD/share | -4.61 USD/share | -6.01 USD/share | -9.35 USD/share |
| Diluted earnings per share | -34.67 USD/share | 0.19 USD/share | -4.61 USD/share | -6.01 USD/share | -9.35 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.